Adavosertib
- Generic Name
- Adavosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32N8O2
- CAS Number
- 955365-80-7
- Unique Ingredient Identifier
- K2T6HJX3I3
- Background
MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
- Conditions
- Cervical CarcinomaEndometrioid AdenocarcinomaMalignant Female Reproductive System NeoplasmRecurrent Cervical CarcinomaStage I Uterine Corpus Cancer AJCC v7Stage I Vaginal Cancer AJCC v6 and v7Stage IA Uterine Corpus Cancer AJCC v7Stage IB Cervical Cancer AJCC v6 and v7Stage IB Uterine Corpus Cancer AJCC v7Stage IB2 Cervical Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT03345784
- Locations
- π¨π¦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
πΊπΈRutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
πΊπΈRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
- Conditions
- Interventions
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT03284385
- Locations
- πΊπΈ
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
πΊπΈSiteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States
πΊπΈUniversity of Kansas Cancer Center, Kansas City, Kansas, United States
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
- Conditions
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT03253679
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈUniversity of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
πΊπΈNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 9
- Registration Number
- NCT03028766
- Locations
- π¬π§
St. James' University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
π¬π§Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
π¬π§The Royal Marsden Hospital, London, United Kingdom
CISPLATIN + AZD-1775 In Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT03012477
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 7
- Registration Number
- NCT02906059
- Locations
- πΊπΈ
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- π©π°
Rigshospitalet, Copenhagen, Denmark
π«π·Gustave Roussy, Villejuif, Val De Marne, France
π³π±Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02688907
- Locations
- π°π·
Keunchil Park, Seoul, Korea, Republic of
Adavosertib Before Surgery in Treating Patients with Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Advanced Fallopian Tube CarcinomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaCarcinomatosisFallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaStage III Fallopian Tube Cancer AJCC V7Stage III Ovarian Cancer AJCC V6 and V7Stage III Primary Peritoneal Cancer AJCC V7
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT02659241
- Locations
- πΊπΈ
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States
πΊπΈM D Anderson Cancer Center, Houston, Texas, United States
πΊπΈMD Anderson West Houston, Houston, Texas, United States
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT02617277
- Locations
- πΊπΈ
Research Site, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.